Human evidence is limited to a handful of small studies for BPC-157 and even less for the rest, long-term safety data doesnt exist, and the compounds sit in a regulatory grey zone that may shift through 2026
We then move to repair by targeting mitochondrial dysfunction, chronic neuroinflammation, glymphatic stasis, and synaptic loss through multimodal bio-interventionsspecifically advanced Photobiomodulation, ketogenic metabolic switching, electromagnetic field therapies, and targeted peptide supplementation
Do not skip this step
Mild nausea and digestive discomfort Some users report mild nausea, particularly when injecting on an empty stomach first thing in the morning
Loading Rapamycin Longevity News Delta Sleep-Inducing Peptide (DSIP) Nick1 January 1, 2026, 4:40pm #22 @Beth , Thanks for sharing the data